Episode Description
A lot of IBD news sounds like it should change your care tomorrow and then… nothing changes at your next appointment. We wanted to close that gap, so we invited back Dr. Victor Chedid and Dr. Iris Wang from Mayo Clinic in Rochester, MN for a Research Rroundup that’s honest about what’s exciting, what’s early, and what still has major caveats for real people living with Crohn’s disease and ulcerative colitis.
We dig into emerging data on GLP-1 agonists like semaglutide and tirzepatide and why several retrospective studies are turning heads with signals for fewer hospitalizations and less steroid use in IBD patients. We also get specific about the “who should not use this” question, including risks for people who are underweight or have disordered eating concerns, and why multidisciplinary support with an IBD dietitian can matter. Robin also raises a practical angle many patients care about: whether GLP-1 medications could help slow gut transit for high ostomy output or pouch output, and what makes insurance approval so challenging.
From there, we talk breakthroughs that could reshape the long game of Crohn’s care: fibrostenotic Crohn’s disease and strictures. An antifibrotic drug targeting intestinal fibroblasts is showing early promise, and we walk through what a phase 2 trial result really means, plus why it can still take years before a therapy becomes available in clinic. We also explore the surprising two-way relationship between sex hormones and the gut microbiome, what that could imply for symptom patterns, and why microbiome testing and “fix your gut” products often outrun the evidence.
We end with what makes us hopeful over the next five years: better biomarkers, precision medicine, and AI in gastroenterology, paired with a clear warning about bias and why ChatGPT-style tools can confidently generate misinformation. If you found this helpful, subscribe, leave a review, and share the episode with someone who needs a clear-eyed update on IBD research.
Links:
- Information from Mt. Sinai about GLP-1 Medications and IBD
- Preventing Fibrosis in IBD: Update on immune pathways and clinical strategies
Let's get social!!
Follow us on Instagram!
Follow us on Facebook!
Follow us on Twitter!